Drug Type ASO |
Synonyms |
Target |
Mechanism MSH3 gene inhibitors(mutS homolog 3 gene inhibitors), DNA damage modulators, RNA interference |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Triplet Therapeutics, Inc.Startup |
Active Organization Triplet Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Huntington Disease | Preclinical | US | Triplet Therapeutics, Inc.Startup | - |
Myotonic Dystrophy | Preclinical | US | Triplet Therapeutics, Inc.Startup | - |
Spinocerebellar Ataxias | Preclinical | US | Triplet Therapeutics, Inc.Startup | - |